A bypass for the Institutional Review Board: Reflections on the Cleveland Clinic study of the Batista operation  by McKneally, Martin F.
and values that govern the behavior of particular cul-
tures, groups, or individuals. In short, an ethic is a sys-
tem of beliefs about “what we should do.” While reli-
gious ethics are grounded in a single coherent view of
values based on a divine perspective,1 secular ethics,
such as the ethic of surgery, are socially constructed.
This means that members of the group (in our case, sur-
geons) come to an agreement about the values and prin-
ciples that will govern our behavior. Surgeons and their
surgical journals are then obliged to conduct themselves
in accordance with those values and principles. 
Let us now look at the issues raised by our reviewers.
1. Were the patients sufficiently informed about
the study?  Reviewers raised concerns about whether
they should consider this article as a report of an obser-
vational study or an experiment. Observational studies
report on the outcomes of treatment as chosen by physi-
cians and patients. The disclosure of information re-
quired for consent to treatment is generally less than
that required for experiments. Experiments require spe-
cial protections for patient-subjects, such as formal con-
sent to be studied as well as treated, approval of the
study protocol by an independent research ethics board,
and, occasionally, oversight by a safety monitoring
mechanism to protect the participants from potential
harms that can befall both investigators and patients.2
Participants in an experiment carry an increased risk of
having their best interests subordinated to a protocol
that requires systematic application and evaluation of
the treatment. Because such studies commit patients
and their physicians to follow an assigned treatment
program, their freedom is restricted. The term “crossing
over” underlines this constraint; a change in treatment
during a study violates a boundary placed around the
choices imposed by the study protocol. The protocol
limits choices for a good reason—to generate data that
can be analyzed to produce generalizable knowledge
about the treatment. Did McCarthy and his colleagues
limit their patients’ choices more than any practicing
surgeon limits choices when performing an operation,
thus committing those patients to a defined treatment?
If so, the patients should be made aware of the limits
imposed by the protocol.
2. Should this study be reviewed by a research ethics
board such as the IRB of The Cleveland Clinic?  What
was troubling our reviewers, I think, is not so much the
W hen I heard the oral presentation of the study ofthe Batista operation conducted by Patrick
McCarthy and his colleagues last May, I shared in the
thrill that was palpable in the audience. Chosen by the
program committee as one of the first presentations at
the meeting of The American Association for Thoracic
Surgery, the study delivered a clear and practical surgi-
cal judgment about the validity of left ventricular reduc-
tion, a new procedure widely regarded as radically
innovative.
We learned that the investigators removed part of the
ventricle in patients judged ill enough to have their
whole heart removed and replaced. The physiological
effects of remodeling the heart were clearly described.
Best of all, the operation was performed in a setting that
could offer the patients a safe fallback procedure, either
mechanical assistance or transplantation.
It seemed an ideal way to “try the treatment out,” test-
ing its efficacy and appropriateness. McCarthy and his
colleagues had built a reliable safety net for their
patients, which would protect them from the substan-
tially higher mortality associated with the operation in
other settings.
When the manuscript describing The Cleveland
Clinic study reached the Journal’s reviewers, it prompt-
ed them to ask several questions that focused on ethical
issues: (1) Were the patients sufficiently informed about
the study? (2) Shouldn’t the study have been reviewed
by a research ethics board such as the Institutional
Review Board (IRB) of The Cleveland Clinic? (3) What
is the Journal’s role in setting or enforcing ethical stan-
dards of patient care and research?
Our Editor, Andrew Wechsler, asked me to comment
on some of the ethical issues and to provide a definition
of ethics. I will begin with the definition: Ethics is a
plural noun,1 referring to various systems of principles
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systematic, somewhat protocol-driven limitation on treat-
ment options. I suspect they were more troubled by the
fact that the Batista operation is a nonvalidated proce-
dure.2,3 Cardiologists and surgeons did not know the
answers to such questions as these: Does this operation
really work? Which patients will benefit? When should
the operation be applied in the course of the illness? 
Every application of a validated treatment to a partic-
ular patient is a quasi-experiment, to see how the treat-
ment works in that particular patient. At some level,
patients know that we are “trying it out” to see if the
treatment will work well for them. However, they have
some assurance that the treatment usually works rea-
sonably well in patients with illness similar to theirs
and is accepted as a valid treatment by informed mem-
bers of the professional community.
In The Cleveland Clinic study, the treatment was also
on trial. When the experiment involves a nonvalidated
treatment, the constraint of a protocol may be intensi-
fied. When the staff become as keen to learn about the
benefits, harms, and other unknown aspects of a treat-
ment as they are to know how it worked in any one of
the patients they are caring for, a competition of inter-
ests arises. The patients are at risk of being used instru-
mentally to gain answers to a series of general ques-
tions that interest the investigators and, among others,
The American Association for Thoracic Surgery
Program Committee and the readers of this Journal.
This risk, and the risk of experiencing unknown effects
of the treatment, are among those that IRBs require
researchers to disclose in the process of informing and
obtaining consent from research subjects.
The IRB was developed to bring greater safety, trans-
parency, and public defensibility to the process of con-
ducting experiments in human patients. The participation
of lay members, chaplains, lawyers, and nurses, as well
as physicians, provides a broader perspective of public
oversight than that provided by community representa-
tives on the institutional board of trustees. The IRB’s
experience with research protocols facilitates a system-
atic approach to thinking about and protecting the inter-
ests of participants in research. The IRB advises the pro-
fessional and administrative staff of the institution only
when it is requested to do so or when it is required by
defined institutional policy to give an opinion. These
requests and requirements are generally triggered by
concerns of the professional staff about an experimental
approach to patient care that is deemed to be outside the
boundary that defines the usual and customary treat-
ments offered to patients. This boundary is fairly clear in
pharmaceutical research, where the pharmacopoeia of
approved drugs and the procedures for testing unap-
proved drugs are defined in the United States by the fed-
eral Food and Drug Administration. The threshold for
requesting the advice of the IRB is not conspicuously
marked in the domain of surgical innovations. Surgical
procedures evolve gradually; surgeons modify tech-
niques and incorporate new materials or devices that
show promise of giving a better outcome as a routine
part of their practice. The boundary between evolution of
validated treatments and the introduction of experimen-
tal nonvalidated treatment is neither well defined nor sta-
ble over time. Since IRBs have finite resources of time,
personnel, and technical knowledge, their oversight of
surgical innovation has natural limits. When should the
advice of this additional institutional safeguard be re-
quested? When should it be required? The answer to
these questions is usually worked out at the local level,
with somewhat haphazard results.
3. What is the Journal’s role in setting or enforc-
ing ethical standards of patient care and research?
The Journal provides a forum for publication of impor-
tant information. When the Journal publishes a manu-
script, it gives implicit approval of the scientific and
ethical value of the work. The ethical standards are
based on the World Medical Association’s Declaration
of Helsinki, Recommendations Guiding Medical
Doctors in Biomedical Research Involving Human
Subjects.4 The Helsinki declaration sets clear require-
ments, including approval by an independent commit-
tee, for experimental studies. It is less clear on new
therapeutic measures. Although their use is accepted
“if it offers hope of saving life, reestablishing health, or
alleviating suffering,” combining research with profes-
sional care for the acquisition of new medical knowl-
edge is circumscribed. “The physician can combine
medical research with professional care [for] the acqui-
sition of new medical knowledge only to the extent that
the . . . research is justified by its potential . . . thera-
peutic value for the patient” [emphasis mine].4 This
standard is reasonable and patient centered, but it pro-
vides insufficient guidance for answering our review-
ers’ questions. The position of the Journal, generally
based on these principles, requires refinement and
specification. Nonvalidated procedures and devices
“that offer hope . . .” are proliferating and entering
practice at an unprecedented rate in this exciting era of
surgical innovation in our specialty.
I will open the dialogue with readers that is needed to
refine our policy by taking a position. I favor a journal
policy that continues the requirement for IRB approval
of experimental studies with well-defined protocols
that can be explained in advance to an IRB and fol-
lowed precisely to validate a research hypothesis. I
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would propose a second mechanism of approval for the
systematic study of nonvalidated surgical procedures
and devices that recognizes the unique features of stud-
ies that attempt to answer the question, “How can we
make this work?” Surgical intuition, unspecifiable in
advance, is pivotal to adapting and modifying new pro-
cedures.5 This unique particularity is readily under-
stood by surgeons, but it perplexes thoughtful people
outside surgery, including many IRB members. 
My proposal draws in part on the experience of
using research protocols approved by larger agencies
such as the cooperative oncology groups. These agen-
cies provide trustworthy background information and
templates for research protocols and consent forms.
This process helps to relieve the burden of reviewing
unknown areas beyond the expertise of a local com-
mittee. An agency like the Joint Society of Thoracic
Surgeons/American Association for Thoracic Surgery
Ad Hoc Committee on New Technology Assessment
might review and approve a surgeon’s protocol for
evaluating a new procedure. A consent form template
emphasizing novelty, the learning curve, the in-
evitability of procedure modifications, planned safety
monitoring, and timely reporting would provide the
flexibility needed to navigate uncharted waters, as
McCarthy and his colleagues did so well.* The
Journal could reasonably accept studies that followed
these protocols without requiring prior approval by
the local IRB. I believe local institutional administra-
tors, practitioners, patients, and the public would view
this bold initiative as evidence that we as a profession
are adapting and constructing our surgical ethic with
integrity and sensitivity to the challenges of evolving
surgical technology.
This editorial is an invitation to our readers to pro-
vide their guidance to the Journal and the profession as
the ethic of surgery evolves. I will summarize the sug-
gestions you send with appropriate acknowledgment in
a subsequent editorial comment.
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*When I talked with Dr. McCarthy about his approach to the ethical
issues discussed here, I learned about the unique environment in
which his research is conducted. Although the authors did not seek
formal approval from the IRB for this study, there is close collabora-
tion and communication with IRB members and a nuanced under-
standing of research ethics among the investigators, one of whom is
a former IRB chairman.
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